Clinical trials: Breast Cancer, Metastatic
Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative…
- Trial name
- NCT05227664
- Testing
- AK117, AK112, Nab paclitaxel
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Akeso
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Breast Cancer, Urothelial Carcinoma
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.
- Trial name
- NCT03523572
- Testing
- Trastuzumab deruxtecan, Nivolumab
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with…
- Trial name
- NCT07487519
- Testing
- HLX43 DOSE 1 IN ≥2L TNBC, HLX43 DOSE 2 IN ≥2L TNBC, HLX43 DOSE 1 + HLX10
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds.
- Trial name
- NCT00191451
- Testing
- Gemcitabine, Carboplatin, Herceptin
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic Breast Cancer
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic…
- Trial name
- B-PRECISE-01 (NCT03767335)
- Testing
- MEN1611, Trastuzumab, Fulvestrant
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 62 people
- Sponsor
- Menarini Group
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.
Breast Cancer
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
- Trial name
- ELONA (NCT05618613)
- Testing
- Elacestrant, Onapristone
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Context Therapeutics Inc.
Breast Cancer, Breast Tumors
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
The purpose of this study is to determine the efficacy (ability to provide a beneficial treatment of the disease) of pralatrexate for the treatment of female patients with advanced or metastatic breast cancer who have failed…
- Conditions
- Breast Cancer, Breast Tumors, Neoplasms, Breast, Cancer of the Breast
- Trial name
- NCT01118624
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 14 sites in United States, Czechia and 2 more
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Locally Advanced or Metastatic Triple-negative Breast Cancer
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously…
- Trial name
- NCT07556848
- Testing
- 9MW2821, Chemotherapy
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Metastatic or Local Advanced Breast Cancer of Patients
A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults
The study is being conducted to evaluate the tolerance, and safety of HRS-8080 tablets monotherapy and combined with other anti-cancer therapy for metastatic or local advanced breast cancer in adults.
- Trial name
- NCT05189717
- Testing
- HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Metastatic Breast Cancer
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
- Trial name
- NCT07071337
- Testing
- SKB264, Nab-paclitaxel, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 430 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.
- Trial name
- MONARCH 1 (NCT02102490)
- Testing
- Abemaciclib
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
This single arm study will assess the efficacy and safety of first line combination treatment with Avastin + docetaxel in patients with HER2 negative metastatic breast cancer.Patients will receive Avastin (15mg/kg iv every 3…
- Trial name
- NCT00774241
- Testing
- bevacizumab [Avastin], docetaxel
- Sponsor
- Hoffmann-La Roche
Healthy Participants, Breast Cancer
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
This study aims to evaluate the feasibility of using See.d instrument and SBS slides for preparation of plasma and cytological samples from whole blood.
- Trial name
- NCT06097156
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.